Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 01/20 04:59:45 pm
248.8 DKK   -0.68%
04:31p GLANCY PRONGAY : Commences Investigation on Behalf of Novo Nordisk ..
01/16 LAWSUIT FOR INV : Nvo)
01/16 NOVO NORDISK A/ : - Share repurchase programme
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.

It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.

The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity.

The Biopharmaceuticals segment involves in the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation, and therapy areas.

The company was founded by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen in 1923 is headquartered in Bagsvćrd, Denmark.

Number of employees : 40 638 persons.
Sales per Businesses
20142015Delta
DKK (in Million)%DKK (in Million)%
Diabetes & Obesity Care69,98078.8%85,59079.3% +22.31%
Biopharmaceuticals18,82621.2%22,33720.7% +18.65%
Sales per Regions
20142015Delta
DKK (in Million)%DKK (in Million)%
North America43,12348.6%56,85752.7% +31.85%
Europe20,15022.7%20,79819.3% +3.22%
International12,54014.1%14,96613.9% +19.35%
China8,0889.1%9,8719.1% +22.05%
Japan & Korea4,9055.5%5,4355% +10.81%
Managers
NameAgeSinceTitle
Lars Fruergaard Jřrgensen, MBA511991President & Chief Executive Officer
Göran Ando682005Chairman
Jesper Brandgaard, MBA541999Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen, PhD571991Chief Science Officer & Executive Vice President
Mads Krogsgaard--Chief Science Officer
Anne Marie Handrup Kverneland611981Director
Stig Strřbćk531992Director
Bruno Francois Jules Angelici, MBA702011Independent Non-Executive Director
Elizabeth Anne Hewitt612012Independent Director
Sřren Thuesen Pedersen, MBA531994Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 2,112,564,000 1,796,581,297 85.0% 52,168,703 2.5% 67.8%
Share B 10 537,436,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Novo Nordisk Fonden 163,814,000 8.14%
Capital Research & Management Co. (World Investors) 147,690,860 7.34%
Novo Nordisk A/S 47,169,175 2.34%
The Vanguard Group, Inc. 38,421,213 1.91%
Norges Bank Investment Management 36,416,979 1.81%
Carmignac Gestion SA 26,680,942 1.33%
Northern Cross LLC 24,934,396 1.24%
Alecta Pension Insurance Mutual 20,908,000 1.04%
BlackRock Fund Advisors 16,146,988 0.80%
Swedbank Robur Fonder AB 14,805,769 0.74%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO B) 47,169,1752.34%1,704,220,878 USD
Nnit A/S (NNIT) 6,375,00025.5%184,479,878 USD
Innate Pharma (IPH) 5,422,70810.1%83,563,388 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
NOVO NORDISK A/S-1.65%72 366
JOHNSON & JOHNSON-0.88%310 685
ROCHE HOLDING LTD.1.29%200 208
PFIZER INC.-2.40%192 367
NOVARTIS AG-3.71%185 489
MERCK & CO., INC.2.48%166 338
SANOFI-0.52%104 512
GLAXOSMITHKLINE PLC-0.67%94 162
BRISTOL-MYERS SQUIBB C..-5.05%92 737
BAYER AG1.33%89 961
ELI LILLY AND CO4.47%84 827
ALLERGAN PLC2.18%80 485
ABBOTT LABORATORIES5.18%69 738
ASTRAZENECA PLC3.22%69 297
SHIRE PLC-4.28%49 690
TAKEDA PHARMACEUTICAL ..-2.69%32 384
ASTELLAS PHARMA INC-4.92%28 996
MYLAN NV-3.15%19 772
EISAI CO., LTD-3.91%16 644
CHUGAI PHARMACEUTICAL ..1.79%16 644
JIANGSU HENGRUI MEDICI..2.24%16 045
Sector Pharmaceuticals - NEC
Novo Nordisk A/S : Connections
Novo Nordisk Holding Ltd.
SWMF Life Science Venture Fund LP
RAND Health
Novo Nordisk Fonden
The International Centre for Missing & Exploited Children
Novo Nordisk Region China A/S
Essex Woodlands Health Ventures UK Ltd.
EUSA Pharma (Europe) Ltd.
Novo A/S
Archimedes Pharma UK Ltd.
Bio*One Capital Pte Ltd.
Novo Nordisk Region Japan & Korea A/S
Novo Nordisk Region North America Ii A/S
Steno Diabetes Center A/S
Novo Nordisk China Pharmaceuticals Co. Ltd.
University of Copenhagen
Hofor Forsyning Komplementar A/S
Essex Bidco Ltd.
Harno Invest A/S
Symphogen A/S
Novo Nordisk Invest 2 A/S
NNE Pharmaplan A/S
Novo Nordisk Region Europe A/S
Novo Nordisk Region International Operations A/S
Silverwood Property Ltd.
Novo Nordisk Gsc Holding A/S
HOFOR Forsyning Holding A/S
Novo Nordisk Pharmaceuticals A/S
Hofor Forsyning A/S
Company contact information
Novo Nordisk A/S
Novo Allé
Bagsvćrd, Capital Region 2880

Phone : +45.44.44.88.88
Web : www.novonordisk.com
© 2017 People , Fundamentals and Ownership